194 related articles for article (PubMed ID: 38086003)
1. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
3. EUS-based Pancreatic Cancer Surveillance in
Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
[TBL] [Abstract][Full Text] [Related]
4. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma.
Kumar S; Saumoy M; Oh A; Schneider Y; Brand RE; Chak A; Ginsberg GG; Kochman ML; Canto MI; Goggins MG; Hur C; Kastrinos F; Katona BW; Rustgi AK
Pancreas; 2021 Jul; 50(6):807-814. PubMed ID: 34149034
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes.
Wang L; Scott FI; Boursi B; Reiss KA; Williams S; Glick H; Yang YX
Clin Gastroenterol Hepatol; 2022 Sep; 20(9):1997-2004.e7. PubMed ID: 34737092
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of Pancreatic Cancer Surveillance in High-Risk Individuals: An Economic Analysis.
Corral JE; Das A; Bruno MJ; Wallace MB
Pancreas; 2019 Apr; 48(4):526-536. PubMed ID: 30946242
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
11. Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program.
Joergensen MT; Gerdes AM; Sorensen J; Schaffalitzky de Muckadell O; Mortensen MB
Pancreatology; 2016; 16(4):584-92. PubMed ID: 27090585
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Abdominal Ultrasound Versus Magnetic Resonance Imaging for Pancreatic Cancer Screening in Familial High-Risk Individuals in Japan.
Kowada A
Pancreas; 2020 Sep; 49(8):1052-1056. PubMed ID: 32769852
[TBL] [Abstract][Full Text] [Related]
14. Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
Wong FL; Lee JM; Leisenring WM; Neglia JP; Howell RM; Smith SA; Oeffinger KC; Moskowitz CS; Henderson TO; Mertens A; Nathan PC; Yasui Y; Landier W; Armstrong GT; Robison LL; Bhatia S
J Clin Oncol; 2023 Feb; 41(5):1046-1058. PubMed ID: 36265088
[TBL] [Abstract][Full Text] [Related]
15. Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
Peters MLB; Eckel A; Lietz A; Seguin C; Mueller P; Hur C; Pandharipande PV
Pancreatology; 2022 Sep; 22(6):760-769. PubMed ID: 35752568
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
Moore SG; Shenoy PJ; Fanucchi L; Tumeh JW; Flowers CR
BMC Health Serv Res; 2009 Jan; 9():9. PubMed ID: 19144138
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102.
Saber W; Bansal A; Li L; Scott BL; Sangaralingham LR; Thao V; Roth JA; Wright W; Steuten LMG; Pidala JA; Mishra A; Maziarz RT; Westervelt P; McGuirk JP; Cutler C; Nakamura R; Ramsey SD
JCO Oncol Pract; 2024 Apr; 20(4):572-580. PubMed ID: 38261970
[TBL] [Abstract][Full Text] [Related]
18. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
[TBL] [Abstract][Full Text] [Related]
20. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
